You just read:

Updated ASCO Guidelines Establish TAILORx-defined Cutoffs for Determining Chemotherapy Benefit with the Oncotype DX Breast Recurrence Score® Test in Node-negative Breast Cancer

News provided by

Genomic Health, Inc.

03 Jun, 2019, 13:00 BST